KR900000547B1 - Pharmaceutical formation for using animal - Google Patents

Pharmaceutical formation for using animal Download PDF

Info

Publication number
KR900000547B1
KR900000547B1 KR1019870004721A KR870004721A KR900000547B1 KR 900000547 B1 KR900000547 B1 KR 900000547B1 KR 1019870004721 A KR1019870004721 A KR 1019870004721A KR 870004721 A KR870004721 A KR 870004721A KR 900000547 B1 KR900000547 B1 KR 900000547B1
Authority
KR
South Korea
Prior art keywords
animal
drug
formulation
animals
lactose
Prior art date
Application number
KR1019870004721A
Other languages
Korean (ko)
Other versions
KR880013577A (en
Inventor
김무곤
안창돈
Original Assignee
김무곤
안창돈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김무곤, 안창돈 filed Critical 김무곤
Priority to KR1019870004721A priority Critical patent/KR900000547B1/en
Publication of KR880013577A publication Critical patent/KR880013577A/en
Application granted granted Critical
Publication of KR900000547B1 publication Critical patent/KR900000547B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

For the composition of medicine for animal use, a mixture containing 1g Na-propionic acid, 50g gelatin, and 900g lactose is dissolved in water, boiled at 150-200 ≰C for evaporation of water, cooled to 80-100 ≰C, then mixed with 20g methionine, homogenized, cooled again to 50-80 ≰C, treated with a proper amount of ethyl vanillin, mixed with 29g lactose, molded into blocks of 10-50Cm dia. to give a final composition.

Description

[발명의 명칭][Name of invention]

동물용 약품제형Veterinary Drug Formulations

[발명의 상세한 설명]Detailed description of the invention

본 발명은 동물용으로 특히 적합한 신규한 약품제형에 관한 것이다.The present invention relates to novel pharmaceutical formulations which are particularly suitable for animals.

종래 약품제형에 관한 연구는 주로 의약품 제형에만 치중되어 왔으며 인간과 전혀 섭식방식이 다른 동물에 적합한 약품의 제형에 관한 연구는 없었다. 따라서 의약품 제형에 준하여 동물에도 산제, 정제, 연고제, 약제, 주사제 등을 투여하였으나 이는 동물 특유의 음식 섭취방식이나 불결한 생활환경 등을 전혀 고려하지 않은 비과학적인 것이었다. 우리나라는 특히 국토가 좁고 여러 가지 경제적인 이유로 좁은 축사에 여러마리의 동물을 밀집사육하는 경우가 많아 동물들의 운동부족을 초래하기 쉽고 이러한 운동부족 증상은 곧 식용감퇴 등으로 동물의 성장을 저해할 뿐아니라 동물 상호간의 충돌등으로 신경이 극히 예민한 상태로 사육되고 있어서 소화불량등의 질환을 일으키는 경우가 많다. 따라서 동물의 생활습관이나 섭식습관에 적합한 약품제형이 절실하나 이제까지의 동물 약품제형은 특별히 개발된 것이 의약품제형과 마찬가지로 산제를 사료에 섞어 먹이는 것이 보통이었다.Previous studies on drug formulations have been mainly focused on pharmaceutical formulations, and there has been no study on the formulation of pharmaceuticals suitable for animals that are completely different from humans. Therefore, according to the pharmaceutical formulations, animals, powders, tablets, ointments, drugs, injections, and the like were administered to the animals, but this was unscientific, which did not consider animal-specific food intake or unclean living environment. In particular, Korea has a small land and many animals are concentrated in a small barn for various economic reasons. Therefore, it is easy to cause the lack of exercise of the animals. In addition, the nerves are raised in a very sensitive state due to the collision between animals, and often cause diseases such as indigestion. Therefore, the drug formulation suitable for the animal's lifestyle or eating habits are urgently needed. However, until now, animal formulations have been specially developed.

그러나 그렇게 사료에 혼합 복용시키는 방법은 약품의 낭비가 많고 사료의 맛을 변하게 하거나 사료에 수시로 혼합해야 하는 번거로움이 있을 뿐아니라 사료와 약품의 반응으로 약품의 효과를 감소시킬 우려가 많았음에도 특별한 방법이 없이 계속 시행해 왔었다.However, the method of mixing and feeding the feed is not only a waste of the drug, it is a hassle to change the taste of the feed or to mix the feed from time to time, as well as to reduce the effectiveness of the drug by the reaction of the feed and the drug is a special method It has been practiced without this.

따라서 본 발명의 목적은 동물들의 생활습관이나 먹이 섭취 방식에 적합하도록 약품제형을 제조하므로서 동물 특유의 스트레스를 해소시키고 운동부족증도 현저히 감소시키며 필요한 영양분 및 약품을 계속적으로 투여할 수 있도록 하는 새로운 동물용 약품 제형을 제공하는 데 있다.Therefore, an object of the present invention is to prepare a drug formulation suitable for the lifestyle or food intake of animals to relieve animal-specific stress, significantly reduce the lack of exercise and to continue to administer the necessary nutrients and drugs for new animals To provide a pharmaceutical formulation.

이러한 목적에 합당한 동물용 약품제형이 되기 위해서는 아래와 같이 조건이 구비된 제형일 필요가 있다.In order to be a suitable animal drug formulation for this purpose it needs to be a formulation with the following conditions.

1. 동물의 후각과 미각, 시각을 동시에 자극할 수 있어야 하고 그 제형에 항상 친근감을 가지고 접근하고 싶은 충동을 주어야 한다. 즉, 동물들이 가지고 장난할 수 있도록 천장이나 기둥에 매달아 둘 수 있도록 해야 한다.1. Must be able to stimulate animal's sense of smell, taste, and vision at the same time and give the urge to approach the formulation in a friendly way. That is, they should be hung on the ceiling or poles so that animals can play with them.

2. 한꺼번에 먹어 치우거나 충격에 깨어지지 않도록 견고해야 한다.2. It should be firm so as not to be eaten at once or broken by impact.

3. 사용되는 원료 성분들을 모두 동물이 복용가능한 것을 뿐아니라 축사내의 불결한 환경에서도 변질되지 않는 안정성이 있어야 한다.3. All raw ingredients used must be stable for animals to be taken, as well as for undamaged conditions in the house.

이상과 같은 목적 및 조건을 갖춘 제형을 연구하던 본 발명자는 본 발명의 약품제형이 이러한 목적 및 조건을 모두 갖춘 제품일을 확인하고 본 발명을 완성하게 되었다.The present inventors who studied the formulations with the above objects and conditions confirmed that the drug formulation of the present invention is a product having all of these objects and conditions and completed the present invention.

본 발명의 제형을 구체적으로 설명하면 기제로서 유당, 포도당, 설탕, 덱스트린 등을 사용하고 동물의 기호에 맞도록 적절한 향미제, 산미제, 고미제, 신미제 등을 첨가하였으며 장기 보존에도 변질되지 않도록 식용가능한 방부제, 방훈제, 항산화제, 방습제를 가할 뿐 아니라 쉽게 깨어지지 않도록 결합제를 첨가하고 원하는 약품을 혼합 제조한다. 이러한 혼합 조성물을 적절한 크기, 예를 들면 직경 10 내지 50㎝의 원주형 또는 다면체 모양의 블럭으로 성형 응고시켜 중앙에 구멍을 뚫고 줄을 매서 기둥이나 천장에 매달아둠으로서 동물들이 수시로 갉아 먹거나 핥아 먹을 수 있도록 하였으며 적절한 놀이기구로도 이용할 수 있도록 하였다.Specifically, the formulation of the present invention uses lactose, glucose, sugar, dextrin, etc. as a base, and adds suitable flavors, acidifying agents, flavoring agents, and sweetening agents to suit the animal's taste, and is edible so as not to deteriorate even in long-term storage. Add preservatives, smoke retardants, antioxidants, desiccants as possible, as well as add binders and mix the desired medicines so that they do not break easily. These mixed compositions can be molded and solidified into appropriately sized, for example, columnar or polyhedral blocks with a diameter of 10 to 50 cm, pierced in the center, lined up and hung on pillars or ceilings, so that animals can be eaten or licked from time to time. It can be used as an appropriate ride.

이와같은 약품제형을 복용시킨 결과 동물들이 이 제형을 가지고 장난을 하거나 적절한 놀이를 할 수 있어 스트레스해소에 도움을 줄 수 있었으며 사료에 약품을 혼합하는 경우의 우려했던 막대한 약품손실도 방지할 수 있었고 약품의 변질을 막을 수 있어 약품의 지속적인 유지가 가능하게 되었다.These drug formulations helped to relieve stress by allowing animals to play with or play with this formulation, and to avoid the enormous drug loss that was associated with mixing the drug into the feed. It is possible to prevent the deterioration of the drug, it is possible to keep the drug.

이하, 본 발명의 제형을 실시예로 설명하면 다음과 같다 :Hereinafter, the formulation of the present invention will be described as follows.

[실시예 1]Example 1

제품 I C1㎏중 성분함량)Ingredients in Product I C1kg)

약효성분 A(메치오닌) 20gActive ingredient A (methionine) 20 g

유당 929gLactose 929 g

젤라틴(결합제) 50g50 g of gelatin (binder)

프로피온산 나트륨(항곰팡이제, 방부제) 1g1 g sodium propionate (antifungal, antiseptic)

에칠 바닐린 적당량(약 1g 정도)Ethyl vanillin (approximately 1 g)

프로피온산 나트륨 1g과 젤라틴 50g을 소량의 물에 용해시키고 여기에 유당 900g을 가한 다음 다시 물을 부가하여 용해시킨 후 150 내지 200℃로 가열하여 대부분의 수분을 증발제거시키고 80 내지 100℃로 냉각시킨다음 메치오닌 20g을 가하여 균일하게 혼화시킨다. 이 혼합물이 50 내지 80℃로 냉각되면 적당한 에칠바닐린을 첨가하고 다시 유당 29g을 가하여 혼합한 다음 적당한 형틀에 부어 24시간이상 방치하여 응고시킨다.Dissolve 1 g of sodium propionate and 50 g of gelatin in a small amount of water, add 900 g of lactose to it, and then add water to dissolve it, heat it to 150 to 200 ° C to evaporate most of the water and cool it to 80 to 100 ° C. 20 g of methionine is added to mix uniformly. When the mixture is cooled to 50-80 ° C., appropriate ethylvanillin is added, lactose 29g is added, mixed, poured into a suitable mold, and left to stand for at least 24 hours for solidification.

[실시예 2]Example 2

제품 II (1㎏중 성분함량)Product II (component content in 1㎏)

비타민 C 2g2 g of vitamin C

포도당 966gGlucose 966 g

폴리비닐알콜 20g20g polyvinyl alcohol

안식향산나트륨 2g2 g sodium benzoate

스테아린산 마그네슘 10g10 g magnesium stearate

비타민 C 2g, 포도당 966g 및 안식향산나트룸 2g을 혼합하여 100메쉬 체를 통과시킨 다음 폴리비닐알콜 20g을 에탄올 200㏄에 용해시킨 결합제액으로 상기 혼합물을 과립화시킨 다음 80㏄이하에서 3 내지 5시간 건조시킨다. 건조된 혼합물을 20메쉬 체에 통과시키고 스테아린산 마그네슘 2g을 가하여 균일하게 혼합하고 적당한 형틀에 넣어 압축 성형시킨다.2g of vitamin C, 966g of glucose and 2g of benzoate are mixed, passed through a 100 mesh sieve, and then the mixture is granulated with a binder solution in which 20g of polyvinyl alcohol is dissolved in 200㏄ of ethanol, and then 3 to 5 hours at 80㏄ or less. To dry. The dried mixture is passed through a 20 mesh sieve, 2 g of magnesium stearate is added, mixed uniformly, and compressed into a suitable mold.

[실시예 3]Example 3

제품 III (1㎏중 성분함량)Product III (component content in 1㎏)

올라퀸독스 3gOlaquin Dogs 3g

백당 946g946 g of white sugar

폴리인산나트륨 50g50 g of sodium polyphosphate

비 에이취 티(BHT) 1gBHT Tea (BHT) 1g

에칠바닐린(향미제) 적당량Ethyl vanillin (flavor)

비 에이취 티 1g 및 백당 946g을 균일하게 혼합하여 가열하여 완전히 용융된 다음 80 내지 100℃로 냉각하여 올라퀸독스 3g 및 에칠바닐린 적당량을 가하여 균일하게 혼합하고 적당한 형틀에 넣어 24시간 방치 응고시킨다.1 g of H. tea and 946 g per bag are mixed uniformly, heated to completely melt, cooled to 80-100 ° C., and 3 g of olquindox and appropriate amount of ethylvanillin are added and mixed uniformly and left to solidify for 24 hours.

[본 발명 제품의 물리학적 성상 시험][Physical property test of the product of the present invention]

[시험 1 : 강도시험][Test 1: Strength test]

상기 실시예 1 내지 3에서 제조한 제품 I 내지 III을 각각 높이 1.7㎝, 직경 1.3㎝ 크기로 잘라 강도를 측정한 결과 아래표에서 보는 바와 같이 만족할 만한 강도를 나타내었다.The products I to III prepared in Examples 1 to 3 were cut into 1.7 cm in height and 1.3 cm in diameter, respectively, and the strength was measured. As a result, the satisfactory strength was shown.

[표 1]TABLE 1

Figure kpo00001
Figure kpo00001

[시험 2 : 물에 대한 용해도][Test 2: Solubility in water]

상기 제품 I 내지 III의 중량이 약 15g이 되도록 정방향 모양으로 자른 다음 충분량의 물속에 넣고 진탕하면서 5분 단위로 용해되었는지를 조사해 본 결과 각 제품의 용해시점은 다음 표와 같이 나타났다. 이 시험으로 본 제품이 습기가 많은 축사내에서도 쉽게 부서지지 않고 장시간 제형을 유지할 수 있음이 증명되었다.지The product I to III was cut into a forward shape so that the weight of about 15g and then put into a sufficient amount of water and stirred for 5 minutes while shaking, as a result of the dissolution time of each product is shown in the following table. This test proved that the product could easily hold the formulation for a long time even in damp houses.

[표 2]TABLE 2

Figure kpo00002
Figure kpo00002

○ : 완전히 용해됨○: completely dissolved

× : 용해되지 않음×: insoluble

[동물중체 및 사료효율 시험]Animal weight and feed efficiency test

동물들은 특별한 질병에 감염되지 않았다 해도 사료나 생활환경이 불결하기 때문에 사육사들이 알게 또는 모르게 수시로 소화기 질환등에 걸리고 또는 자동치유되는 것을 반복하게 된다. 본 발명자들은 본 발명의 약품제형을 축사내에 비치함으로써 그러한 사소한 질환들까리 예방 또는 치료할 수 있었으며 동물의 체중이 증가되고 사료효율이 크게 개선됨을 다음과 같은 비교실험에서 확인할 수 있었다.Even if the animal is not infected with a particular disease, the feed or living environment is unclean, so that the zookeepers often suffer from diseases of the digestive organs or auto-healing without knowing or not knowing. The present inventors were able to prevent or treat such minor diseases by keeping the pharmaceutical formulation of the present invention in the barn, and it was confirmed in the following comparative experiment that the animal's weight is increased and feed efficiency is greatly improved.

[비교실험 1][Comparative Experiment 1]

평균제층 7.5㎏인 이유자돈 20두를 각각 10두씩 2개의 시험구로 나누어 한쪽의 시험구에는 본 발명제품을 투여하고 다른 한쪽의 비교시험구에는 투여하지 않은 채 통상의 사용방법에 따라 3주 동안 사육하였다. 시험기간중의 사료급여는 일반 시판 배합사료를 무제한 급여하였고 그 시험기간 동안 본 발명 제품의 블록은 1개만 소모되었다. 시험기간후에 각 시험구의 자돈체중 및 사료섭취량을 비교 측정해 본 결과는 다음 표에 나타낸 바와 같이 비교 시험구에 비하여 본 발명 제품의 블록을 투여한 시험구가 각각 18.5% 및 5.7%만큼 향상되어 본 발명 제품의 효과를 충분히 인정할 수 있었다.20 heads of weaning piglets with a mean weight of 7.5 kg were divided into two test groups, each of 10 heads, and were reared for three weeks according to the usual method of administration without administering the present invention product to one test group and the other test group. . Feeding during the trial was given an unlimited number of commercially available formulated feeds and only one block of the invention product was consumed during the trial. After the test period, the piglet weight and feed intake of each test group were measured and compared with the test group, as shown in the following table, the test group administered the block of the product of the present invention was improved by 18.5% and 5.7%, respectively. The effect of the invention product was fully recognized.

[표 3]TABLE 3

Figure kpo00003
Figure kpo00003

* 시험결과의 수치는 시험구당 평균치임.* The results of the test are averaged per test zone.

[비교실험 2][Comparative Experiment 2]

평균체중 8.2㎏인 이유자돈을 공시하여 비교실험 1과 동일한 방법으로 실험 결과 다음 표에 나타난 바와 같이 비교시험구에 비하여 본 발명의 블록투여구가 중체량 및 사료요구율에서 각각 13.8% 및 7.1% 개선되어 본 발명 제품의 효과를 재확인할 수 있었다.Experimental results of the weaning pigs with an average weight of 8.2 kg showed the same results as in Comparative Experiment 1, and as shown in the following table, the block-dose of the present invention was improved by 13.8% and 7.1% in the weight and feed requirements, respectively. The effect of the product of the present invention could be reconfirmed.

[표 4]TABLE 4

Figure kpo00004
Figure kpo00004

Claims (2)

기재로서 유당, 백당, 포도당, 덱스트린으로부터 선택된 1이상의 당류와 동물용 약품 및 1이상의 방부제 결합제를 함유하는 조성물을 직경 10 내지 50㎝의 블록형상으로 성형제조한 동물용 약품제형.An animal pharmaceutical formulation formed by molding a composition containing at least one sugar selected from lactose, white sugar, glucose and dextrin as a substrate, an animal drug and at least one preservative binder in a block shape having a diameter of 10 to 50 cm. 제1항에 있어서, 당류의 함량이 60% 이상이고 제형의 강도가 10㎏/㎠이상인 동물용 약품제형.The veterinary pharmaceutical formulation according to claim 1, wherein the saccharide content is at least 60% and the strength of the formulation is at least 10 kg / cm 2.
KR1019870004721A 1987-05-14 1987-05-14 Pharmaceutical formation for using animal KR900000547B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019870004721A KR900000547B1 (en) 1987-05-14 1987-05-14 Pharmaceutical formation for using animal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019870004721A KR900000547B1 (en) 1987-05-14 1987-05-14 Pharmaceutical formation for using animal

Publications (2)

Publication Number Publication Date
KR880013577A KR880013577A (en) 1988-12-21
KR900000547B1 true KR900000547B1 (en) 1990-01-31

Family

ID=19261396

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870004721A KR900000547B1 (en) 1987-05-14 1987-05-14 Pharmaceutical formation for using animal

Country Status (1)

Country Link
KR (1) KR900000547B1 (en)

Also Published As

Publication number Publication date
KR880013577A (en) 1988-12-21

Similar Documents

Publication Publication Date Title
DE3220557C2 (en)
DE60319969T2 (en) TASTEFUL FIXED MEDICINAL PRODUCTS FOR ANIMALS
JPS641442B2 (en)
JP2000514406A (en) Enteric coating consisting of alginic acid for oral administration
JPH0115303B2 (en)
WO2005016358A1 (en) Anthelmintic formulations
US7582612B2 (en) Multi-action anthelmintic formulations
CN111714470B (en) Enteric-coated sodium iron ethylene diamine tetraacetate premix for livestock and preparation method thereof
KR900000547B1 (en) Pharmaceutical formation for using animal
US20060067954A1 (en) Lipid stabilized formulations
CZ280981B6 (en) Preparation in the form of pellets
US2893914A (en) Thiadicarbocyanine anthelmintic compositions and methods of using them
US6174866B1 (en) Edible anti-parasite medication for domesticated animals
DE60023119T2 (en) COMPOSITIONS FOR THE ADMINISTRATION OF A CYCLOOXYGENASE-2 HEMMER TO ANIMALS
KR101688093B1 (en) The composition of ivermectin chewable tablet and method for manufacturing thereof
KR101109036B1 (en) The composition of fenbendazole oral tablet and method for manufacturing thereof
JP3142192B2 (en) Blood lipid improving agent and composition containing the same
CN104208657A (en) Virginiamycin soluble powder and preparation method thereof
JP3878011B2 (en) Livestock mastitis preventive
JP7534139B2 (en) Veterinary medicines
JP3512552B2 (en) Arteriosclerosis inhibitor and food or medicine containing it
EP3583937B1 (en) Excipient free glucosamine tablets and methods of making
CN101524335A (en) Paracetanol orally-disintegrating tablet for beasts and birds and preparation method thereof
RU2056857C1 (en) Method for controlling reproduction function of female pigs and increasing survival period of their offsprings
Done et al. Sedation and restraint of fallow deer with diazepam

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19990201

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee